Vascular and renal effects of anti-angiogenic therapy;Effets vasculaires et rénaux des médicaments anti-angiogéniques : recommandations françaises pour la pratique (SN, SFHTA, APNET, FFCD)

Nephrologie et Therapeutique

Volumn 4, Issue 7, 2008, Pages 602-615

  Halimi, Jean Michel ^a   Azizi, Michel ^b   Bobrie, Guillaume ^b   Bouché, Olivier ^c   Deray, Gilbert ^d   des Guetz, Gaetan ^e   Lecomte, Thierry ^a   Levy, Bernard ^f   Mourad, Jean Jacques ^e   Nochy, Dominique ^b   Oudard, Stéphane ^b   Rieu, Philippe ^c   Sahali, Dil ^g  

^a UNIVERSITÉ DE TOURS   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f HÔPITAL LARIBOISIÈRE   (France)

^g HENRI MONDOR HOSPITAL   (France)

Author keywords

Anti angiogenic drugs; Cancer; Hypertension; Kidney; Proteinuria; Safety; Side effects; Treatments; VEGF; Vessels

Indexed keywords

ALPHA2A INTERFERON; AMLODIPINE; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CISPLATIN; DILTIAZEM; DIURETIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NIFEDIPINE; OXALIPLATIN; PAZOPANIB; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; VERAPAMIL;

ARTERIAL PRESSURE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BREAST CANCER; CARDIOTOXICITY; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; GENERAL PRACTITIONER; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY INJURY; LEUKOENCEPHALOPATHY; LIVER CELL CARCINOMA; MALIGNANT HYPERTENSION; NEPHRITIS; NEPHROLOGIST; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; QT PROLONGATION; SHORT SURVEY; STROKE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; COLORECTAL NEOPLASMS; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; HUMANS; INDOLES; KIDNEY; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC; PROTEINURIA; PYRIDINES; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 57049125046     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2008.10.002     Document Type: Short Survey

References (61)

1. Miles D. Management of toxicity in patients receiving therapy with bevacizumab. Eur J Cancer (2008) 29-39
2. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
3. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Rev 4 (2004) 581-611
4. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
5. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
6. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
7. Results of a Phase III randomized placebo-controlled trial (SHARP study), Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib improves survival in advanced hepatocellular carcinoma. J Clin Oncol 25 (2007) LBA1
8. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
9. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
10. Rini B.I., and Rathmell W.K. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res 13 (2007) 741s-746s
11. Remontet L., Estève J., Bouvier A.M., et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 51 (2003) 3-30
12. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
13. Ferrara N., Berber H.N., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
14. Fukumura D., Xavier R., Sugiura T., et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94 (1998) 715-725
15. Houck K.A., Ferrara N., Winer J., et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5 (1991) 1806-1814
16. Tischer E., Mitchell R., Hartman T., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266 (1991) 11947-11954
17. Keyt B.A., Berleau L.T., Nguyen H.V., et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 271 77 (1996) 88-95
18. Le Tourneau C., Faivre S., and Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 34 (2008) 37-48
19. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 (1997) 4593-4599
20. Muller Y.A., Chen Y., Christinger H.W., et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 6 (1998) 1153-1167
21. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65 (2005) 671-680
22. A randomized phase III study, Saltz L.B., Clarke S., Díaz-Rubio E., et al. Bevacizumab in combination with Oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer. J Clin Oncol 26 (2008) 2013-2019
23. Results from the Eastern Cooperative Oncology Group Study E3200, Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer. J Clin Oncol 25 (2007) 1539-1544
24. A randomized phase II study of the AIO GI tumor study group, Schmiegel W.H., Reinacher-Schick A., Freier W., Dietrich G., Arnold D., Kanzler S., et al. Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC). J Clin Oncol 25 Suppl. 18S (2007) 4034a
25. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
26. George D.J., Michaelson M.D., Rosenberg J.E., et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers. Proc Am Soc Clin Oncol 25 (2007) 243s
27. http://ctep.cancer.gov/reporting/ctc.html (site consulté le 8 septembre 2008).
28. Azizi M., Chedid A., and Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 358 (2008) 95-97
29. Glusker P., Larry Recht L., and Lane L. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354 (2006) 980-981
30. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107 (2003) 1359-1365
31. Mourad J.J., des Guetz G., Debbabi H., and Levy B.I. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19 (2008) 927-934
32. Veronese M.L., Mosenkis A., Flaherty K.T., Gallagher M., Stevenson J.P., Townsend R.R., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24 (2006) 1363-1369
33. Zhu X., Wu S., Dahut W.L., and Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49 (2007) 186-193
34. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
35. George B.A., Zhou X.J., and Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 49 (2007) e23-29
36. Izzedine H., Brocheriou I., Rixe O., and Deray. Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 22 (2007) 241
37. Eremina V., Jefferson J.A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358 (2008) 1129-1136
38. Frangié C., Lefaucheur C., Medioni J., et al. Renal thrombotic microangiopathy caused by anti-VEGFantibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 8 (2007) 177-178
39. Izzedine H., Brocheriou I., Deray G., et al. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 22 (2007) 1481-1482
40. Ayllon J, Janus N, Launay-Vacher V, et al. Anti-VEGF therapies, cancer and renal function. J Clin Oncol 26: 2008 suppl; abstr 16001.
41. Sugimoto H., Hamano Y., Charytan D., Cosgrove D., Kieran M., Sudhakar A., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278 (2003) 12605-12608
42. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 (2003) 649-658
43. Strevel E.L., Ing D.J., and Siu L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25 (2007) 3362-3371
44. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 (2007) 2011
45. http://www.has-sante.fr/portail/display.jsp?id=c_272459 (site consulté le 8 septembre 2008).
46. http://afssaps.sante.fr/htm/5/liste_tensio_1.htm (site consulté le 8 septembre 2008).
47. Modification of diet in renal disease study group, Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
48. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
49. ESH-ESC Task force on the management of arterial hypertension, Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens 25 (2007) 1751-1762
50. Wolter P., Dumez H., and Schoffski P. Sunitinib and hypothyroidism. N Engl J Med 356 (2007) 1580
51. Rixe O., Billemont B., and Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 18 (2007) 1117
52. van Heeckeren W.J. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?. J Clin Oncol 25 (2007) 2993-2995
53. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
54. Dincer M., and Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother 40 (2006) 2278-2279
55. Roncone D., Satoskar A., Nadasdy T., Monk J.P., and Rovin B.H. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 3 (2007) 287-293
56. Barakat R.K., Singh N., Lal R., Verani R.R., Finkel K.W., and Foringer J.R. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Ann Pharmacother 41 (2007) 707-710
57. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
58. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
59. Sun S., and Schiller J.H. Angiogenesis inhibitors in the treatment of lung cancer. Crit Rev Oncol Hematol 62 (2007) 93-104
60. Rugo H.S., Herbst R.S., Liu G., Park J.W., Kies M.S., Steinfeldt H.M., et al. Phase I trial of the oral anti-angiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23 (2005) 5474-5483
61. Wu S., Chen J.J., Kudelka A., Lu J., and Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9 (2008) 117-123